Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
A Pilot Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Patricia Graham, MS
- Phone Number: 3052435119
- Email: pgraham1@med.miami.edu
Study Contact Backup
- Name: Mark S Nash, PhD
- Phone Number: 305.243.3628
- Email: mnash@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami - Miami Project to Cure Paralysis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female individuals with paraplegia having chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from T2-T8
- Male and female individuals wi4.th chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from C4-C7
Exclusion Criteria:
- Pregnant or planning to become pregnant
- Women who are breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: UA and exercise in paraplegia group
Participants will take UA 4 capsules twice daily for 12 weeks while participating in an exercise program, 3 times per week.
|
Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session.
Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets.
The arm selected for exercise will be randomized.
|
|
Experimental: UA in tetraplegia group
Participants will take UA 4 capsules twice daily for 12 weeks
|
Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Muscle Mass Using Dual X-ray Absorptiometry (DXA)
Time Frame: Baseline, 12 weeks
|
Changes in muscle mass in grams as measured by Dual X-ray Absorptiometry
|
Baseline, 12 weeks
|
|
Changes in Peak Isokinetic Strength
Time Frame: Baseline, 12 weeks
|
Peak strength (peak torque in ft-lb) of both arms at 90 degrees range of motion will be tested in elbow flexion and extension (at 60 deg/s) on a Biodex dynamometer
|
Baseline, 12 weeks
|
|
Changes in Fasting Insulin Resistance (IR)
Time Frame: Baseline, 12 weeks
|
Changes in IR using Homeostatic Model of Assessment (HOMA) v2 model estimates steady state beta cell function and insulin sensitivity as percentages of a normal reference population.
The change in resting IR will be measured by (fasting serum glucose*fasting serum insulin/22.5).
Lower values indicate a higher degree of insulin sensitivity.
|
Baseline, 12 weeks
|
|
Changes in Glucose Disposal
Time Frame: Baseline, 12 weeks
|
Changes in glucose disposal will be measured by the Oral Glucose Tolerance Test (OGTT) using Trutol glucose solution of 75 grams.
The rates of glucose disposal will be defined by the area under the glucose challenge curve (AUC).
|
Baseline, 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mark S Nash, PhD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Metabolic Diseases
- Glucose Metabolism Disorders
- Hyperinsulinism
- Trauma, Nervous System
- Spinal Cord Diseases
- Atrophy
- Paralysis
- Wounds and Injuries
- Spinal Cord Injuries
- Insulin Resistance
- Muscular Atrophy
- Quadriplegia
- Paraplegia
- Anti-Infective Agents
- Antineoplastic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- Analgesics
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
- Antineoplastic Agents, Phytogenic
- Ursolic Acid
Other Study ID Numbers
Other Study ID Numbers
- 20221142
- COPBC (Other Identifier: State of Florida)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.